biotech / news / / LBC
Wegovy maker Novo Nordisk said surging demand for its first weight loss pill has put it on track to beat trading forecasts.
Novo Nordisk's Wegovy pill launch is the strongest of any US obesity drug to date.
KEY POINTS
- The company has reported over two million Wegovy pill prescriptions since its January launch.
- Quarterly Wegovy pill sales were 2.26 billion Danish krone, surpassing analyst expectations.
- Novo Nordisk raised 2026 guidance for adjusted sales and operating profit due to Wegovy's success.
- Wegovy is currently the only oral peptide therapy for obesity on the market.
COMPANIES
Summarized by Newsio from LBC. How we summarize →